A Pilot Trial of "Just ASK™" to Increase Discussions About Breast Cancer Clinical Trials
NCT ID: NCT07040891
Last Updated: 2025-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
80 participants
INTERVENTIONAL
2026-01-31
2026-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Is a cluster RCT feasibility and acceptable? (This will inform the design of a future definitive cluster RCT)
* What are the determinants of the Just Ask training completion and implementation in practice to develop a better understanding for whom the intervention works, and under what circumstances?
* What are the discussion elements and approaches that are associated with participation in breast cancer clinical trials?
Researchers will compare the intervention arm (breast cancer clinics assigned to the Just ASK training) with the control arm (clinics receiving no training) to evaluate differences in clinical trial discussions with eligible breast cancer patients. Clinic participants in the intervention arm will complete the training and develop an implementation plan of training framework. Across all participating practices, up to 20 patient encounters per practice will be recorded to identify discussion elements associated with clinical trial participation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bilingual Breast Cancer Educational Intervention for Hispanic Women With Stage I, Stage II, or Stage III Breast Cancer and Their Families or Caregivers
NCT01043003
Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice
NCT04297384
Feasibility of a Supportive Education Program for Latina Breast Cancer Survivors
NCT01628887
Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344
NCT00897026
Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients
NCT00270894
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Just ASK training arm
Participants in this arm will complete "Just ASK™" training, a web-based program designed to help providers understand the impact of assumptions about their patients' interest in cancer clinical trials and describe the "Just ASK™" framework for systematically asking all patients about cancer clinical trials.
Just ASK training
"Just ASK™" is a web-based training designed to help providers understand the impact of assumptions about their patients' interest in cancer clinical trials. The training framework aims to increase clinical trial discussions with all cancer patients.
Usual care arm
Participants in the usual care arm will not receive the training intervention.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Just ASK training
"Just ASK™" is a web-based training designed to help providers understand the impact of assumptions about their patients' interest in cancer clinical trials. The training framework aims to increase clinical trial discussions with all cancer patients.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to provide informed consent.
* Age \>18
* New or relapsed patients diagnosed with breast cancer
* Are evaluated at the Abramson Cancer Center by those oncology team members participating in this study
* Are able to provide informed consent.
Exclusion Criteria
\- Already consented to participate in a breast cancer clinical trial for their treatment
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Pennsylvania
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Carmen E. Guerra
Ruth C. and Raymond G. Perelman Professor of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carmen E Guerra, MD
Role: PRINCIPAL_INVESTIGATOR
University of Pennsylvania
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Castillo BS, Boehmer L, Schrag J, Howson A, Oyer R, Pierce L, Barrett NJ, Guerra CE. Oncologist-Reported Barriers and Facilitators to Offering Cancer Clinical Trials to Their Patients. Curr Oncol. 2024 May 28;31(6):3017-3029. doi: 10.3390/curroncol31060230.
Barrett NJ, Boehmer L, Schrag J, Benson AB 3rd, Green S, Hamroun-Yazid L, Howson A, Matin K, Oyer RA, Pierce L, Jeames SE, Winkfield K, Yang ES, Zwicker V, Bruinooge S, Hurley P, Williams JH, Guerra CE. An Assessment of the Feasibility and Utility of an ACCC-ASCO Implicit Bias Training Program to Enhance Racial and Ethnic Diversity in Cancer Clinical Trials. JCO Oncol Pract. 2023 Apr;19(4):e570-e580. doi: 10.1200/OP.22.00378. Epub 2023 Jan 11.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BCRF-24-205
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.